NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis → AI Bubble Now at Critical Mass (From Porter & Company) (Ad) Free OPRX Stock Alerts $12.27 +0.12 (+0.99%) (As of 02:04 PM ET) Add Compare Share Share Today's Range$11.65▼$12.4050-Day Range$11.47▼$16.1752-Week Range$6.92▼$16.65Volume215,410 shsAverage Volume118,368 shsMarket Capitalization$222.70 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get OptimizeRx alerts: Email Address OptimizeRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside29.6% Upside$16.00 Price TargetShort InterestHealthy4.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 6 Articles This WeekInsider TradingSelling Shares$60,760 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.66) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.36 out of 5 starsComputer And Technology Sector335th out of 587 stocksBusiness Services, Not Elsewhere Classified Industry58th out of 90 stocks 3.4 Analyst's Opinion Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, OptimizeRx has a forecasted upside of 29.6% from its current price of $12.35.Amount of Analyst CoverageOptimizeRx has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.72% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in OptimizeRx has recently decreased by 3.31%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPRX. Previous Next 1.9 News and Social Media Coverage News SentimentOptimizeRx has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 6 news articles for OptimizeRx this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for OPRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,760.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.66) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -15.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -15.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI Bubble Now at Critical MassWashington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.Simply click here now to read The Big AI Die-Up. About OptimizeRx Stock (NASDAQ:OPRX)OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.Read More OPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPRX Stock News HeadlinesMarch 27, 2024 | msn.comOptimizeRx Q4 2023 Earnings PreviewMarch 27, 2024 | benzinga.com7OPRX : OptimizeRx Earnings PreviewMarch 28, 2024 | Porter & Company (Ad)AI Bubble Now at Critical MassWashington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.March 27, 2024 | americanbankingnews.comOptimizeRx (OPRX) to Release Earnings on ThursdayMarch 25, 2024 | globenewswire.comOptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ETMarch 23, 2024 | seekingalpha.comOptimizeRx: Exponential Growth Drives The Valuation CheaperMarch 18, 2024 | americanbankingnews.comOptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), AnaptysBio (ANAB) and REPRO-MED Systems (KRMD)March 28, 2024 | Porter & Company (Ad)AI Bubble Now at Critical MassWashington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.March 11, 2024 | markets.businessinsider.comOptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023March 11, 2024 | globenewswire.comOptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023March 6, 2024 | stockhouse.comOptimizeRx Powers Walmart's 'Specialty Pharmacies of the Community' Outreach EffortMarch 4, 2024 | globenewswire.comOptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community' Outreach EffortFebruary 23, 2024 | benzinga.comOptimizeRx Stock (NASDAQ:OPRX), Short Interest ReportFebruary 21, 2024 | globenewswire.comOptimizeRx to Participate in Upcoming Investor ConferencesJanuary 9, 2024 | finanznachrichten.deOptimizeRx Corporation: OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business UpdateJanuary 9, 2024 | finance.yahoo.comOptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business UpdateJanuary 4, 2024 | msn.comBarclays Initiates Coverage of OptimizeRx (OPRX) with Equal-Weight RecommendationJanuary 3, 2024 | realmoney.thestreet.comOptimizeRx initiated with neutral view at BarclaysDecember 26, 2023 | finance.yahoo.comShould You Exit OptimizeRx Corp. (OPRX)?December 23, 2023 | benzinga.comOptimizeRx Stock (NASDAQ:OPRX) Dividends: History, Yield and DatesDecember 18, 2023 | finance.yahoo.comOptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San FranciscoDecember 11, 2023 | finance.yahoo.comOptimizeRx Corp. (OPRX) Upgraded to Buy: What Does It Mean for the Stock?December 11, 2023 | finance.yahoo.comWith 74% institutional ownership, OptimizeRx Corporation (NASDAQ:OPRX) is a favorite amongst the big gunsDecember 6, 2023 | msn.comWall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should KnowDecember 6, 2023 | finance.yahoo.comWall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should KnowNovember 21, 2023 | finance.yahoo.comWhy OptimizeRx Corp. (OPRX) Might be Well Poised for a SurgeSee More Headlines Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Confirmed)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees109Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$20.00 Low Stock Price Target$13.00 Potential Upside/Downside+30.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,440,000.00 Net Margins-21.88% Pretax Margin-21.88% Return on Equity-9.24% Return on Assets-8.71% Debt Debt-to-Equity RatioN/A Current Ratio11.35 Quick Ratio11.35 Sales & Book Value Annual Sales$62.45 million Price / Sales3.57 Cash FlowN/A Price / Cash FlowN/A Book Value$7.35 per share Price / Book1.67Miscellaneous Outstanding Shares18,150,000Free Float17,353,000Market Cap$223.25 million OptionableOptionable Beta1.01 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. William J. Febbo (Age 55)CEO & Director Comp: $694.4kMr. Stephen L. Silvestro (Age 46)President Comp: $458.6kMr. Edward Stelmakh C.M.A. (Age 58)M.B.A., CFO & COO Comp: $547.05kMr. Andrew Jacob D'SilvaSenior Vice President of Corporate FinanceMr. Todd Inman (Age 68)Chief Technology Officer Ms. Marion K Odence-Ford (Age 59)General Counsel & Chief Compliance Officer Comp: $428.12kMaira AlejandraMedia Relations ManagerMs. Sheryl KearneyHuman Resources ManagerMr. Terence J. Hamilton (Age 59)Senior Vice President of Pharma Comp: $441.63kDr. Doug Besch (Age 42)Chief Product Officer More ExecutivesKey CompetitorsRimini StreetNASDAQ:RMNIZeroFoxNASDAQ:ZFOXDHI GroupNYSE:DHXLimelight NetworksNASDAQ:LLNWSteel ConnectNASDAQ:STCNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 28,416 shares on 3/11/2024Ownership: 5.625%Greenwood Capital Associates LLCBought 20,245 shares on 3/5/2024Ownership: 0.301%Goldman Sachs Group Inc.Sold 30,985 shares on 3/1/2024Ownership: 0.074%Quarry LPSold 4,188 shares on 2/20/2024Ownership: 0.021%Citadel Advisors LLCBought 1,700 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions OPRX Stock Analysis - Frequently Asked Questions Should I buy or sell OptimizeRx stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks. What is OptimizeRx's stock price target for 2024? 6 Wall Street analysts have issued twelve-month target prices for OptimizeRx's shares. Their OPRX share price targets range from $13.00 to $20.00. On average, they predict the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts. How have OPRX shares performed in 2024? OptimizeRx's stock was trading at $14.31 at the beginning of the year. Since then, OPRX stock has decreased by 13.7% and is now trading at $12.35. View the best growth stocks for 2024 here. When is OptimizeRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our OPRX earnings forecast. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) issued its earnings results on Tuesday, November, 9th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by $0.04. The business had revenue of $16.13 million for the quarter, compared to analysts' expectations of $14.82 million. OptimizeRx had a negative trailing twelve-month return on equity of 9.24% and a negative net margin of 21.88%. During the same period in the previous year, the company posted ($0.01) earnings per share. What ETFs hold OptimizeRx's stock? ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD).Global X Telemedicine & Digital Health ETF (EDOC). What guidance has OptimizeRx issued on next quarter's earnings? OptimizeRx issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $100.0 million-, compared to the consensus revenue estimate of $110.4 million. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN). Who are OptimizeRx's major shareholders? OptimizeRx's stock is owned by a number of retail and institutional investors. Top institutional investors include First Light Asset Management LLC (9.52%), Vanguard Group Inc. (5.63%), Vanguard Group Inc. (5.63%), G2 Investment Partners Management LLC (2.58%), Dimensional Fund Advisors LP (1.41%) and Federated Hermes Inc. (1.01%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.